Core Laboratories NV (CLB)
Return on equity (ROE)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | ||
|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | 31,400 | 26,196 | 23,708 | 37,522 |
| Total stockholders’ equity | US$ in thousands | 251,991 | 250,742 | 240,274 | 232,155 |
| ROE | 12.46% | 10.45% | 9.87% | 16.16% |
December 31, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $31,400K ÷ $251,991K
= 12.46%
Core Laboratories NV's return on equity (ROE) has shown a fluctuating trend over the four quarters of the fiscal year 2024. In March 2024 and December 2024, the ROE was relatively higher at 16.16% and 12.46% respectively, indicating that the company generated a decent return for its shareholders during these periods. However, there was a decline in ROE in the following quarters, with values of 9.87% in June 2024 and 10.45% in September 2024.
The decline in ROE in the middle two quarters could suggest potential changes in the company's profitability or efficiency in utilizing shareholders' equity to generate earnings. It would be crucial for stakeholders to further investigate the factors contributing to these fluctuations to assess the long-term sustainability of Core Laboratories NV's profitability and its ability to create value for shareholders.
Peer comparison
Dec 31, 2024